Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression.
BMC Urol
; 12: 21, 2012 Aug 16.
Article
em En
| MEDLINE
| ID: mdl-22898175
ABSTRACT
BACKGROUND:
Prevention of bladder cancer recurrence is a central challenge in the management of this highly prevalent disease. The histone deacetylase inhibitor valproic acid (sodium valproate) has anti-angiogenic properties and has been shown to decrease bladder cancer growth in model systems. We have previously shown reduced expression of thrombospondin-1 in a mouse model and in human bladder cancer relative to normal urothelium. We speculated that inhibition of angiogenesis by valproate might be mediated by this anti-angiogenic protein.METHODS:
Bladder cancer cell lines UMUC3 and T24 were treated with valproate or another histone deacetylase inhibitor, vorinostat, in culture for a period of three days. Proliferation was assessed by alamar blue reduction. Gene expression was evaluated by reverse transcription of RNA and quantitative PCR.RESULTS:
Proliferation assays showed treatment with valproate or vorinostat decreased proliferation in both cell lines. Histone deacetylase inhibition also increased relative expression of thrombospondin-1 up to 8 fold at 5 mM valproate.CONCLUSIONS:
Histone deacetylase inhibitors warrant further study for the prevention or treatment of bladder cancer.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Regulação Neoplásica da Expressão Gênica
/
Ácido Valproico
/
Trombospondina 1
/
Proliferação de Células
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article